Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells 14,569 Shares of Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the transaction, the insider directly owned 4,318,348 shares in the company, valued at $30,487,536.88. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.34, for a total transaction of $158,712.82.

Entrada Therapeutics Stock Performance

NASDAQ:TRDA traded down $0.62 on Wednesday, hitting $7.00. The stock had a trading volume of 229,319 shares, compared to its average volume of 334,500. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The firm’s fifty day simple moving average is $7.08 and its two-hundred day simple moving average is $9.36. The stock has a market cap of $272.58 million, a P/E ratio of -1.77 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Equities research analysts predict that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the stock. Odyssean LLC purchased a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $230,000. Nantahala Capital Management LLC purchased a new position in Entrada Therapeutics in the second quarter valued at approximately $2,212,232,000. Public Employees Retirement System of Ohio purchased a new position in Entrada Therapeutics in the second quarter valued at approximately $276,000. Bank of America Corp DE bought a new position in Entrada Therapeutics during the second quarter valued at $426,000. Finally, 5AM Venture Management LLC bought a new position in Entrada Therapeutics during the second quarter valued at $29,854,949,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Roth Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Weiss Ratings cut Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Entrada Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.75.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.